在渐进的多发性硬化症中,T淋巴细胞介导的突触细胞再次出现
Krizia Sanna1, Antonio Bruno2,3, Sara Balletta3
1Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Frontiers in immunology
|June 24, 2024
概括
来自二级渐进性多发性硬化症 (SPMS) 患者的T细胞恶化了神经元刺激能力. 西波尼莫德是一种斯芬戈-1-酸盐受体调节剂,可以逆转这种T细胞诱导的突触毒性,为进展性MS提供潜在的治疗标.
科学领域:
- 神经免疫学 神经免疫学
- 神经药理学神经药理学
- 多发性硬化症的发病因子
背景情况:
- 二次渐进性多发性硬化症 (SPMS) 的特点是,在复发性缓解性多发性硬化症 (RRMS) 过程后,不可逆转的残疾累积.
- 目前的治疗方法缺乏可靠跟踪RRMS到SPMS过渡的工具.
- 来自RRMS患者的T细胞加剧了神经元刺激性传播,这是一个没有缓解的突触毒性事件.
研究的目的:
- 调查T细胞介导的突触毒性在SPMS期间重新出现的假设.
- 在SPMS中探索siponimod的突触保护作用,这是一个sphingosine 1-phosphate受体 (S1PR) 调节器.
主要方法:
- 从健康对照组 (HC),SPMS患者和接受西波尼莫德治疗的SPMS患者收集的数据.
- 用人类T细胞在小鼠皮层-状切片上进行了嵌合体实验,以记录谷氨酸活性.
- 用EAE小鼠T细胞和S1PR调节器进行同源的仿真实验,以确定涉及的特定受体.
主要成果:
- 与HC T细胞相比,来自SPMS患者的T细胞显著增加了状刺激性突触传播.
- 西波尼莫德治疗有效地挽救了SPMS患者衍生的T细胞诱导的突触毒性.
- 同类的模拟实验确定了S1P5R作为Siponomod保护作用中介的受体.
结论:
- 从RRMS过渡到SPMS与T细胞介导的突触毒性再次出现有关.
- 西波尼莫德在抵消T细胞诱导的兴奋毒性方面表现出有效性.
- 炎症性突触症是进展性多发性硬化症的一个重要因素,是有前途的治疗点.
相关概念视频
T Cell Types and Functions
999
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
999
Long-term Potentiation
55.1K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.1K


